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2. Abstract  3 
Background 4 
Limited data suggests that an altered metabolic and cardiorespiratory exercise response may affect 5 
exercise performance in individuals with Huntington’s disease (HD). There is no clear exploration of 6 
the response in individuals at different stages of the disease or in relation to genetic markers. This 7 
study aimed to examine the exercise response and recovery of HD participants, and the relationship 8 
to genetic and clinical markers. 9 
Method 10 
HD gene-positive participants (n=31; 9 pre-manifest; 22 manifest HD) and a healthy control group 11 
(n=29) performed an incremental exercise test until exhaustion. Performance, cardiorespiratory, 12 
metabolic and perceptual responses to exercise were determined from a maximal cycle ergometer 13 
test throughout the exercise test and during a recovery period.  14 
Results 15 
During sub-maximal exercise, metabolic (lactate levels, oxygen uptake) and cardiorespiratory markers 16 
(heart rate) were elevated in HD participants compared to controls. Lactate elevation was specific to 17 
pre-manifest HD participants. Work capacity was reduced in both pre-manifest and manifest HD 18 
participants with tests terminated with no difference in metabolic, perceptual or cardiorespiratory 19 
markers. Submaximal oxygen uptake was correlated with motor score, whilst peak measures were 20 
unrelated to genetic or clinical markers. Heart rate recovery was attenuated in pre-manifest and 21 
manifest HD participants. 22 
Conclusions 23 
Our findings confirm metabolic and cardiorespiratory deficits reduce exercise performance and affect 24 
recovery from an early stage in HD, with submaximal deficits related to phenotypic expression. 25 
Exercise capacity appears to be limited by an altered movement economy, thus clinicians should 26 
consider an altered exercise response and recovery may affect prescription in HD.  27 
 28 
 29 
 30 
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3. Introduction 31 
Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a polyglutamine 32 
stretch within the Huntingtin gene1. Neuropathology causes progressive motor disturbances, 33 
cognitive dysfunction and psychiatric symptoms2. However, as the mutant Huntingtin gene is 34 
ubiquitously expressed, people with HD also experience an array of peripheral organ dysfunctions, 35 
including a severe metabolic phenotype, weight loss, abnormal fat and glucose homeostasis, 36 
cardiomyopathy, skeletal muscle wasting and reduced muscle strength3–6.  37 
In healthy people, exercise interventions reduce all-cause mortality and are beneficial for 38 
cardiorespiratory fitness, muscle strength, mental health and cognition7–10. Exercise prescription has 39 
also been shown to be safe, feasible and in some cases, beneficial for motor symptoms in HD11–13. 40 
However, results have been variable and detrimental effects of exercise training have also been 41 
reported4,14. These conflicting and variable findings may reflect an altered physiological and 42 
perceptual response to exercise in HD15 which may consequentially affect exercise prescription 43 
outcomes. Importantly, the variability in the response to exercise suggests that targeted exercise 44 
prescription may be required for people with HD. 45 
In order to develop targeted approaches, it is necessary to understand what factors affect the 46 
pathophysiological response to exercise. The current study was designed to improve knowledge on 47 
who may benefit from exercise prescription by understanding individual exercise responses. Previous 48 
work has found manifest HD participants experience an early increase in blood lactate and a reduced 49 
work capacity and peak oxygen consumption, with no abnormalities in peak cardiac and ventilatory 50 
performance16. Cardiac alterations and differences in perceived exertion were also found at lower 51 
exercise intensities in HD participants prior to commencing an exercise intervention15, and an 52 
increased oxygen cost of exercise has been demonstrated11.  53 
Previous studies in HD showing an altered exercise response were measured at a distinct 54 
exercise stage, most commonly the response to maximal exercise intensity11,17, whilst 55 
cardiorespiratory and metabolic recovery after exercise has not been previously studied in HD. Here, 56 
we measured the incremental response to exercise across the entirety of a cardiopulmonary test and 57 
recovery period. We hypothesised that the physiological responses to the submaximal, maximal and 58 
recovery phases may differ between controls and HD participants, which may relate to clinical and 59 
genetic disease markers.  60 
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4. Methods 61 
Participants 62 
Thirty-one HD participants (22 manifest, 9 pre-manifest) were recruited from specialist HD clinics in 63 
Cardiff, UK and Oxford, UK. Twenty-nine gene-negative controls were matched for age, gender and 64 
self-reported physical activity levels. Demographic and clinical data are shown in Table 1. Data was 65 
collected with ethical approval and participants gave informed consent. 66 
Exercise protocol 67 
Participants completed an incremental cycle ergometer exercise test18 (Excalibur Sport, Lode, 68 
Netherlands) involving two minutes of rest, two minutes of unloaded cycling, followed by 25-watt 69 
increments every two minutes, starting at 50-watts (Supplementary Figure 1). The exercise test was 70 
symptom limited; individuals pedalled at 50 revolutions/minute until discomfort or fatigue due to 71 
effort prevented them from maintaining the work rate. A 10-point Borg Scale measured perceived 72 
exertion, fatigue in the legs and dyspnea. At 2 minute intervals, Borg ratings were collected along with 73 
whole blood capillary lactate concentration (Lactate pro, UK).  74 
Pulmonary gas exchange was measured on a breath-by-breath basis (MetaMax 3B, Cortex 75 
Biophysik GmbH, Leipzig, Germany) and averaged every 30-seconds. Direct measurements of oxygen 76 
consumption (O2), carbon dioxide production (CO2), minute ventilation (VE), and derived variables 77 
including the respiratory exchange ratio (RER, i.e., O2/CO2), oxygen pulse (O2/HR) and the ventilatory 78 
equivalents for oxygen (VE/O2) and carbon dioxide (VE/CO2) were obtained. Heart rate was 79 
continuously recorded using short-range telemetry (Polar S810, Finland).  80 
After reaching exhaustion, participants cycled at an unrestrained speed at 25-watts for 2 81 
minutes. Participants then transferred to a seated position and heart rate, blood pressure, lactate and 82 
Borg ratings were recorded every 2-minutes for 10-minutes. Additional protocol details can be found 83 
in the supplementary information.  84 
Clinical and genetic measures  85 
The motor component (TMS) of the UHDRS  and the Total Functional Capacity (TFC)19 score were 86 
recorded. Self-reported physical activity levels were recorded using the International Physical Activity 87 
Questionnaire [IPAQ]20. CAG repeat length data was available for 19 HD participants. To assess 88 
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baseline cognition, participants completed the Trail Making Test (part B) and The Symbol Digit 89 
Modalities Test (SDMT). 90 
Statistical analyses 91 
HD participants were stratified according to disease stage (see Table 1; manifest HD participants = TFC 92 
score < 13 and TMS >18, Supplementary Figure 2 shows TFC range in manifest group).  93 
 As sample size differed across test stages due to different termination points, multiple univariate 94 
analyses of variance (ANOVA’s) assessed group differences at each test stage (rest, submaximal stages 95 
[50-, 75-, 100- and 125-watts], and peak performance), using SPSS software [IBM, version 23]. Multiple 96 
comparisons were corrected for using the false discovery rate (FDR) at p < 0.05. Where results survived 97 
the FDR correction, Bonferroni-adjusted post-hoc pairwise analyses examined group differences. 98 
Multivariate ANOVA’s were conducted for the recovery measures with post-hoc Bonferroni-adjusted 99 
analyses. 100 
Where group differences were found, the relationship with clinical and genetic data was tested using 101 
a Pearson’s correlation analysis.  102 
A slope analysis assessed the relationship between physiology measures and work rate, from rest to 103 
peak. The oxygen uptake efficiency slope (OUES)21, was determined from rest to peak using the 104 
following equation: 105 
𝑉𝑉𝑉𝑉2̇ = 𝑎𝑎 log  𝑉𝑉?̇?𝑉 + 𝑏𝑏; 106 
Where a represents the OUES, the rate of increase in V02 in response to VE. 107 
 108 
[Table 1 here] 109 
5. Results 110 
Despite no significant difference in age, BMI, and IPAQ score between control and HD participants 111 
overall (all p > 0.05), manifest HD participants were significantly older than pre-manifest HD and 112 
controls participants, thus age was included as a covariate in all analyses.  113 
Exercise protocol compliance 114 
Four HD participants were excluded from the analysis as they were unable to achieve the required 115 
speed of 50 revolutions/min (see Supplementary Table 1). One HD participant experienced syncope 116 
following maximal exertion.  117 
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Resting measures  118 
Resting VO2, heart rate, RER, mean arterial blood pressure (MAP) and lactate levels did not different 119 
between HD participants and controls (p > 0.05, Figure 1). Perceptually, there was no difference in 120 
resting ratings of fatigue (p > 0.05).  121 
Submaximal exercise function 122 
Exercise parameters across test stages are shown in Figure 1.  123 
Physiology. VO2 was elevated in manifest HD participants compared to controls at 50 watts (33% 124 
increase, F2,50 = 5.42, p = 0.006) and 75 watts (24.3% increase, F2,50 = 3.45, p = 0.035) with no 125 
differences between pre-manifest and control participants (p > 0.05). Similarly, heart rate was 126 
elevated in manifest HD participants compared to controls at 50 and 75 watts (F2, 49 = 5.54 and 6.47 127 
respectively, p < 0.05). In pre-manifest participants, heart rate was elevated compared to controls at 128 
75 watts only (p = 0.024).  129 
There was a main effect of group (HD vs. controls) on lactate levels at 50 watts (F1,37 = 5.36, p = 0.035), 130 
75 watts (F1,35 = 8.21, p = 0.028) and 100 watts (F1,34 = 5.90, p = 0.034). Lactate was higher in pre-131 
manifest HD participants compare to controls, surviving Bonferroni correction at 75 and 100 watts (p 132 
= 0.014 and 0.039) but not 50 watts (controls vs. manifest HD, p = 0.053). The difference between 133 
controls and manifest HD participants was significant at 50 and 75 watts (p = 0.027 and 0.049 134 
respectively) before age was accounted for, however with age as a covariate, this difference was not 135 
significant. 136 
Results from the slope analysis are shown in Supplementary Table 2. There was no difference in the 137 
OUES nor the relationship between work rate and V02, heart rate and lactate between control and HD 138 
participants (all p > 0.05).  139 
Perceptual responses. There were no group difference in perceived exertion ratings at any workload 140 
between 50 and 125 watts (p > 0.05).  141 
[Figure 1 here] 142 
 143 
 144 
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Peak exercise capacity  145 
Figure 2 shows the individual and group data at exhaustion. Age-adjusted marginal means are shown 146 
in Supplementary Table 3.  147 
Performance. Volitional exhaustion occurred at a lower working capacity (Wpeak) in HD participants 148 
(F1,53 = 11.26, p = 0.001, Figure 2A). Pre-manifest and manifest participants had a lower Wpeak 149 
compared to controls (p = 0.049 and 0.026 respectively); there was no difference in Wpeak between 150 
pre-manifest and manifest HD participants (p > 0.05). 151 
Physiology. There were no differences in V�02 peak, heart rate, oxygen pulse, RER, VE, VE/VCO2 152 
(controls = 28.9 ± 0.8; pre-manifest = 30.7 ± 1.4; manifest HD = 30.0 ± 1.0), VE/O2 (controls = 35.5 ± 153 
1.4; pre-manifest = 33.2 ± 2.1; manifest HD = 34.9 ± 1.6) at exhaustion between HD and control 154 
participants (p > 0.05).  155 
Blood lactate production was 25.3% lower in HD participants at exhaustion compared to controls (F1,40 156 
= 9.37, p = 0.004, Figure 2E) and was lower in manifest HD participants compared to controls (p = 157 
0.032). Pre-manifest HD participants did not differ from controls. To determine the effect of Wpeak 158 
on lactate production, peak lactate levels were normalised by Wpeak. There was no difference in 159 
normalised peak lactate between control and HD participants (controls = 0.057 ± 0.003; pre-manifest 160 
HD = 0.060 ± 0.004; manifest HD = 0.050 ± 0.003, p > 0.05).  161 
Perceptual responses. There were no differences in perceived exertion ratings between HD 162 
participants and control participants at volitional exhaustion (p > 0.05).  163 
[Figure 2 here] 164 
Exercise recovery 165 
Physiology. On a group level, heart rate did not differ between HD and control participants (Figure 166 
3A). To examine individual variability in heart rate recovery (HRR), the change in heart rate from peak 167 
was calculated. HRR was slower in HD participants compared to controls (F10,70 = 1.98, p < 0.05, Figure 168 
3B). HRR was higher in controls compared to manifest HD participants at 2-minutes post exercise (p = 169 
0.011), whereas after 4-minutes, HRR was higher in controls compared to pre-manifest and manifest 170 
participants (p = 0.038 and 0.007 respectively). At 6-, and 8-minutes post exercise, HRR remained 171 
higher in controls compared to pre-manifest participants (p = 0.016 and 0.021 respectively). There 172 
were no differences in HRR between manifest and pre-manifest HD participants. Ten minutes 173 
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following exercise, the difference between HRR in pre-manifest participants and controls was not 174 
significant (p = 0.07). 175 
Lactate levels were reduced in manifest HD participants compared to controls at 2- and 4-minutes 176 
post exercise (p = 0.012 and 0.034 respectively, Figure 3C), with no differences between control and 177 
pre-manifest HD participants, and pre-manifest and manifest HD participants. To account for peak 178 
lactate levels, lactate change (from peak) was calculated. There were no differences between control 179 
and HD participants in lactate change during recovery (p>0.05, Figure 3D). 180 
Perceptual response. Self-reported ratings of fatigue during the recovery phase did not differ 181 
between HD and control participants (Figure 3, p > 0.05).  182 
 [Figure 3 here] 183 
 184 
Relationship between exercise measures and genetic and phenotypic HD expression  185 
UHDRS TMS, where a higher score indicates greater movement disorder, was correlated with VO2 at 186 
50 watts (r= 0.49, p = 0.032), and 75 watts (r = 0.44, p = 0.041, Supplementary Figure 3). There was no 187 
correlation between submaximal VO2 and UHDRS TFC or CAG repeat length (all p > 0.05). Heart rate 188 
at 50- and 75-watts, and lactate levels at 50-, 75- and 100-watts were not correlated with cUHDRS 189 
TMS and TFC or CAG repeat length, all p > 0.05.  190 
No correlations were found between clinical data (UHDRS TMS and TFC), CAG repeat length and peak 191 
lactate or Wpeak, all p > 0.05.  192 
The correlation between HRR at 4- and 6-minutes post exercise and the UHDRS TMS (r = -0.40 and -193 
0.40, p = 0.039 and 0.041 uncorrected) and UHDRS TFC (r = 0.38 and 0.46, p = 0.053 and 0.017 194 
uncorrected) was not significant after multiple comparison adjustments. 195 
 196 
6. Discussion 197 
This study shows an altered exercise response in people with HD during a graded exercise test. Despite 198 
normal resting physiology, upon initiation of low intensity exercise, heart rate, lactate, and oxygen 199 
uptake were elevated in HD participants compared to controls, suggestive of a movement economy 200 
deficit and altered metabolism. The early elevation in lactate was observed in pre-manifest HD 201 
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participants specifically, suggesting that abnormal oxidative metabolism in skeletal muscle may be an 202 
early feature of HD prior to functional decline. In contrast, elevated oxygen uptake at low intensities 203 
was related to greater motor dysfunction in HD participants. In agreement with previous work16, 204 
volitional exhaustion occurred at a lower working capacity in HD participants and both pre-manifest 205 
and manifest HD participants produced less lactate at maximal effort. Almost one fifth of manifest HD 206 
participants were unable to maintain the required cycling speed, highlighting an altered exercise 207 
tolerance and physical ability in HD. 208 
The altered cardiorespiratory and metabolic response to exercise may account for the variable 209 
responses to exercise prescription previously reported in HD17. The relationship between oxygen 210 
uptake during submaximal exercise and motor functioning suggest some of the variability can be 211 
accounted for by phenotypic disease expression, however metabolic differences were not accounted 212 
for by genetic load or phenotype, and were evident in pre-manifest HD participants, suggesting a 213 
complex physiological response to exercise in HD.  214 
Notably, these novel findings provide support for individualised exercise prescription, and 215 
suggest that the effect of long-term exercise training may vary between individuals based on the 216 
prescribed exercise intensity and their subsequent physiological response. Further studies measuring 217 
the response to exercise are therefore recommended throughout the prescription period in order to 218 
understand if disturbances in exercise response interact with exercise prescription outcomes. In 219 
addition, it would be valuable to measure creatine kinase following exercise to explore muscle cell 220 
disturbance in HD and to further explore autonomic functioning. 221 
Whereas previous work has shown a reduced V�02 peak in manifest HD16, we failed to replicate 222 
this. The discrepancy is most likely explained by the inclusion of age as a covariate in this study; when 223 
V02 was measured as a percent of theoretical maximum capacity according to age, body type, and sex, 224 
differences due to HD were no longer observed16. In line with previous work16, HD participants had a 225 
normal ventilatory response to maximal exercise and both clinical data and genetic data did not 226 
predict peak measures. CAG repeat length was also not predictive of the submaximal physiological 227 
response, suggesting that genetic markers are insensitive to exercise response in HD. The rate of V�02 228 
may be affected by how effectively oxygen is delivered to the muscles (respiratory and cardiovascular 229 
systems), how it is utilised (metabolic systems) and how hard the muscles are working (neuromuscular 230 
systems). We propose that higher VO2 at submaximal exercise and not at peak may be due to muscles 231 
working harder in people with HD due to chorea and/or poor co-ordination which requires greater 232 
oxygen use. At peak exercise, aerobic metabolism is limited due to issues with bioenergetics and 233 
mitochondrial functioning in the HD group. 234 
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After reaching exhaustion, heart rate recovery was attenuated in HD participants. This is a 235 
novel finding; impaired heart rate recovery is an independent predictor of mortality in healthy 236 
populations22. The fall in heart rate immediately after exercise is a function of the reactivation of the 237 
parasympathetic nervous system, mediated by vagal reactivation in the first two minutes of 238 
recovery23. It is not clear whether vagal reactivation continues to mediate heart rate recovery for the 239 
eight minutes observed here, or whether other mechanisms drive the slowed response. Due to the 240 
cool-down protocol used, it is not possible to compare heart rate recovery with normative data 241 
attained immediately after exhaustive exercise cessation, however our findings complement work 242 
showing reduced cardiovagal modulation in middle-stage HD24,25. The elevated heart rate observed 243 
during submaximal exercise in HD participants replicates Dawes et al.15 and increases the robustness 244 
of the observation that people with HD do not reach steady heart rates when initiating low-intensity 245 
exercise. This is informative for exercise prescription; applying objective submaximal markers as 246 
opposed to training intensities based on maximal measures (e.g. heart rate, VO2), and measuring 247 
exercise recovery as an indicator of intervention effectiveness may be more appropriate. 248 
The difference observed in peak lactate is most likely driven by differences in task 249 
performance. Working capacity was reduced in HD participants, and when peak lactate was 250 
normalised for maximal work rate, the lactate differences were no longer significant. This suggests 251 
that HD participants were unable to work as hard on the exercise test which contributed to the lower 252 
lactate levels and is supported by previous work showing a reduced work capacity in manifest 253 
participants16. The reduced working capacity in pre-manifest HD participants suggests an underlying 254 
energy deficit rather than reduced muscle bulk.  255 
Altered metabolism was also evident during submaximal exercise. The failure of oxidative 256 
mechanisms can affect lactate production and clearance and previous work has shown elevated 257 
lactate production in symptomatic HD participants during a cardiopulmonary test at 50 watts and 75 258 
watts16. We replicated this finding, however, lactate was also significantly higher in pre-manifest HD 259 
participants compare to controls at 75 and 100 watts, whereas the difference between controls and 260 
manifest HD participants was not significant after accounting for age. The discrepancy in the results 261 
may be partly explained by higher fitness levels in the current cohort and a broader symptomatic HD 262 
group.  263 
A common limitation in clinical exercise research is the physiological effect of medication. 264 
Participants in this study were prescribed a diverse range of medications which alter metabolic 265 
pathways26. It is not known if observed metabolic and cardiac deficits are a cause or consequence of 266 
HD toxicity, and/or mediated by medication. A comprehensive large-scale study is required to unpick 267 
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medication effects, with the metabolic consequences of drugs in the same sub-class varying 268 
substantially due to differences in receptor pharmacology. Metabolic deficits observed in animal 269 
models and cell cultures of HD suggest that observed effects are not purely driven by medication27,28, 270 
however they may account for some variability in exercise prescription responses.  271 
Overall, we have demonstrated that metabolic and cardiorespiratory deficits contribute towards a 272 
reduced exercise performance and affects recovery in HD. Autonomic dysfunction has been reported 273 
in a variety of neurodegenerative dementias29,30 and further work is required to elucidate whether 274 
deficits are a direct consequence of peripherally expressed mutant huntingtin protein, or secondary 275 
to a general decline in health or neurological dysfunction. This knowledge will be crucial for targeted 276 
exercise prescription in HD and for determining outcome measures. 277 
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8. Figure Legends  358 
 359 
Figure 1 Response to submaximal exercise. Results are marginal means adjusted for age, error bars = standard errors of the 360 
mean. RER: Respiratory exchange rate. RPE: Ratings of perceived exertion. * p < 0.05 Bonferroni-adjusted. † unadjusted p < 361 
0.05. preHD: pre-manifest, HD: manifest HD. 362 
 363 
 364 
Figure 2 Peak exercise response at test termination. Black line represents mean; grey box depicts 95% CI. RER: respiratory 365 
exchange ratio (VC02: VO2); RPE: Rating of perceived exertion. PreHD: pre-manifest HD participants. HD: Manifest HD 366 
participants. P-values are Bonferroni- adjusted. 367 
 368 
Figure 3 Recovery response [B] & [D] show absolute change from peak. Results are marginal means adjusted for age. Error 369 
bars = standard errors of the mean. RPE: rating of perceived exertion. HR: heart rate (beats/minute). * p < 0.05, ** p < 0.01. 370 
